Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

Image from the source feed · MarketWatch

Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.

OpenBook market desk: Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.

Why this matters for multi-asset traders

The headline theme is "Citi tells investors it’s time to sell Moderna after 600%-plus stock gains". We reframe the story for readers tracking equities, FX majors and crypto liquidity - without copying the original wording.

Watch related price action on OpenBook movers and treat this note as information, not investment advice.

Based on reporting from MarketWatch. Read the original.

This briefing was summarized with automated tools from public reporting by MarketWatch and is general market information, not investment advice. Editorial policy & corrections